Application using non-covalent bond between a cucurbituril derivative and a ligand

ABSTRACT

Provided are a kit including a first component that is a compound of formula (1) below bound to a first material and a second component that is a ligand bound to a second material, wherein each of the first and second materials is independently selected from the group consisting of a solid phase, a biomolecule, an antioxidant, a chemical therapeutic agent, an anti-histaminic agent, a cucurbituril dendrimer, a cyclodextrin derivative, a crown ether derivative, a calixarene derivative, a cyclophane derivative, a cyclic peptide derivative, a metallic ion, a chromophore, a fluorescent material, a phosphor, a radioactive material, and a catalyst; and the ligand can non-covalently bind to the compound of formula (1); a method of separating and purifying a material bound to a ligand using the compound of formula (1) bound to a solid phase; a method of separating and purifying the compound of formula (1) or a material bound to the compound using a ligand bound to a solid phase; a sensor chip including a compound of formula (1) bound to a first material and a ligand bound to a second material; and a solid-catalyst complex including the compound of formula (1) bound to a first material and a ligand bound to a second material.

CROSS-REFERENCE TO RELATED PATENT APPLICATIONS

This application claims the benefit of Korean Patent Application No.10-2005-0099379, filed on Oct. 20, 2005, Korean Patent Application No.10-2005-0108312, filed on Nov. 12, 2005, Korean Patent Application No.10-2006-0000891, filed on Jan. 4, 2006, and Korean Patent ApplicationNo. 10-2006-0018434, filed on Feb. 24, 2006, in the Korean IntellectualProperty Office, the disclosure of which is incorporated herein in itsentirety by reference.

BACKGROUND OF THE INVENTION

1. Field of the Invention

The present invention relates to a kit comprising a first component thatis a compound of formula (1) bound to a first material and a secondcomponent that is a ligand bound to a second material and capable ofnon-covalently binding to a cucurbituril derivative; a method ofseparating and purifying a material bound to a ligand using a compoundof formula (1) bound to a solid phase; a method of separating andpurifying a compound of formula (1) or a material bound to the compoundof formula (1) using a ligand bound to a solid phase; a sensor chipcomprising a complex of a compound of formula (1) bound to a firstmaterial and a ligand bound to a second material; and a solid-catalystcomplex comprising a compound of formula (1) bound to a first materialand a ligand bound to a second material.

2. Description of the Related Art

Host molecules, such as cyclodextrin (U.S. Pat. No. 4,539,399), andcrown ether (Korean Patent No. 026382), have the ability to retain guestmolecules in their structure and thus research has been conducted intotheir application in separating and removing materials. To use such ahost molecule as a column packing material, the host molecule has to becovalently bound to a solid substrate selected from among polymers, suchas silica gel, zeolite, titanium oxide, cellulose, etc. Such hostmolecules covalently bound to solid substrates are used as stationaryphases of various column packing materials for column chromatography andused to separate various samples.

Cucurbituril was first reported by R. Behrend, E. Meyer, F. Rusche in1905 (Liebigs Ann. Chem. 1905, 339, 1). W. Mock et al. characterizedcucurbituril as a hexameric macrocyclic compound having the chemicalformula of C₃₆H₃₆N₂₄O₁₂ and confirmed the chemical structure by X-raydiffraction (J. Am. Chem. Soc. 1981, 103, 7367). They named thiscompound cucurbit[6]uril. Since then, improved synthetic methods ofcucurbit[6]uril have been disclosed (refer to DE 196 03 377 A1).

Cucurbituril is a macrocyclic compound having a lipophilic cavity andtwo hydrophilic entrances at upper and lower portions. Accordingly,lipophilic interactions occur in the cavity of cucurbituril, andhydrogen bonds, polar-polar interactions, positive charge-polarinteractions, etc. occur in the two entrances having n carbonyl groups.Therefore, cucurbituril has the ability to retain various compoundsthrough more stable non-covalent bonding bond than commonly usedcyclodextrin. In addition, cucurbituril has the ability to retain ionicmaterials and large-polarity materials, for examples, various organicmaterials, such as gaseous compounds, aliphatic compounds, aromaticcompounds, etc., and various compounds, such as insecticides,herbicides, amino acids, nucleic acids, ionic compounds, metallic ions,organic metallic ions, etc. (J. Am. Chem. Soc. 2001, 123, 11316:European Patent No. 1094065; and J. Org. Chem. 1986, 51, and 1440).

SUMMARY OF THE INVENTION

The present invention provides a kit comprising a cucurbiturilderivative bound to a particular material and a ligand bound to aparticular material and capable of non-covalently binding to thecucurbituril derivative.

The present invention provides a method of separating and purifying amaterial bound to a ligand capable of non-covalently binding to acucurbituril derivative using the cucurbituril derivative bound to asolid phase.

The present invention provides a method of separating and purifying acucurbituril derivative capable of non-covalently binding to a ligandusing the ligand bound to a solid phase, or a material bound to thecucurbituril derivative.

The present invention provides a sensor chip comprising a complex of acucurbituril derivative bound to a particular material and a ligandbound to a particular material.

The present invention provides a solid-catalyst complex comprising acucurbituril derivative bound to a particular material and a ligandbound to a particular material.

According to an aspect of the present invention, there is provided a kitcomprising: a first component that is a compound of formula (1) bound toa first material; and a second component that is a ligand bound to asecond material, wherein each of the first and second materials isindependently selected from the group consisting of a solid phase, abiomolecule, an antioxidant, a chemical therapeutic agent, ananti-histaminic agent, a cucurbituril dendrimer, a cyclodextrinderivative, a crown ether derivative, a calixarene derivative, acyclophane derivative, a cyclic peptide derivative, a metallic ion, achromophore, a fluorescent material, a phosphor, a radioactive material,and a catalyst; and

the ligand can non-covalently bind to a compound of formula (1) below,has at least one amine group, and is selected from the group consistingof a C₁-C₂₀ alkyl group; a C₂-C₂₀ alkenyl group; a C₂-C₂₀ alkynyl group;a C₁-C₂₀ alkoxy group; a C₁-C₂₀ aminoalkyl group; a C₄-C₂₀ cycloalkylgroup; a C₄-C₇ heteroarylcyclo group; a C₆-C₂₀ aryl group; a C₅-C₂₀heteroaryl group; a C₁-C₂₀ alkylsilyl group; a C₆-C₂₀ aryl group; aC₅-C₂₀ heteroaryl group; adamantane having a substituted ornon-substituted C₁-C₂₀ alkyl group, C₆-C₂₀ aryl group or C₅-C₂₀heteroaryl group; ferrocene or metallocene having a substituted ornon-substituted C₁-C₂₀ alkyl group, C₆-C₂₀ aryl group or C₅-C₂₀heteroaryl group; carborane having a substituted or non-substitutedC₁-C₂₀ alkyl group, C₆-C₂₀ aryl group or C₅-C₂₀ heteroaryl group;fullerene having a substituted or non-substituted C₁-C₂₀ alkyl group,C₆-C₂₀ aryl group or C₅-C₂₀ heteroaryl group; cyclam or crown etherhaving a substituted or non-substituted C₁-C₂₀ alkyl group, C₆-C₂₀ arylgroup or C₅-C₂₀ heteroaryl group; an oxygen-protected amino acid havinga substituted or non-substituted C₁-C₂₀ alkyl group, C₆-C₂₀ aryl groupor C₅-C₂₀ heteroaryl group; peptide having a substituted ornon-substituted C₁-C₂₀ alkyl group, C₆-C₂₀ aryl group or C₅-C₂₀heteroaryl group; alkaloid having a substituted or non-substitutedC₁-C₂₀ alkyl group, C₆-C₂₀ aryl group or C₅-C₂₀ heteroaryl group;cisplatin having a substituted or non-substituted C₁-C₂₀ alkyl group,C₆-C₂₀ aryl group or C₅-C₂₀ heteroaryl group; oligonucleotide having asubstituted or non-substituted C₁-C₂₀ alkyl group, C₆-C₂₀ aryl group orC₅-C₂₀ heteroaryl group; rhodamine having a substituted ornon-substituted C₁-C₂₀ alkyl group, C₆-C₂₀ aryl group or C₅-C₂₀heteroaryl group; and a nanoparticle having a substituted ornon-substituted C₁-C₂₀ alkyl group, C₆-C₂₀ aryl group or C₅-C₂₀heteroaryl group,

where n is an integer from 6 to 10;

X is O, S or NH;

each of A₁ and A₂ is independently H, OR, SR, or NHR, and A₁ and A₂ arenot simultaneously H, where R is selected from the group consisting ofH; a substituted or non-substituted C₁-C₃₀ alkyl group; a substituted ornon-substituted C₂-C₃₀ alkenyl group; a substituted or non-substitutedC₂-C₃₀ alkynyl group; a substituted or non-substituted C₂-C₃₀carbonylalkyl group; a substituted or non-substituted C₁-C₃₀ thioalkylgroup; a substituted or non-substituted C₁-C₃₀ alkylthiol group; asubstituted or non-substituted C₁-C₃₀ hydroxyalkyl group; a substitutedor non-substituted C₁-C₃₀ alkylsilyl group; a substituted ornon-substituted C₁-C₃₀ aminoalkyl group; a substituted ornon-substituted C₁-C₃₀ aminoalkylthioalkyl group; a substituted ornon-substituted C₅-C₃₀ cycloalkyl group; a substituted ornon-substituted C₂-C₃₀ heterocycloalkyl group; a substituted ornon-substituted C₆-C₃₀ aryl group; a substituted or non-substitutedC₆-C₃₀ arylalkyl group; a substituted or non-substituted C₄-C₃₀heteroaryl group; and a substituted or non-substituted C₄-C₃₀heteroarylalkyl group.

According to another aspect of the present invention, there is provideda method of separating and purifying a material bound to a ligand, thematerial being selected from the group consisting of a solid support ora biomolecule, an antioxidant, a chemical therapeutic agent, ananti-histaminic agent, a cucurbituril dendrimer, a cyclodextrinderivative, a crown ether derivative, a calixarene derivative, acyclophane derivative, a cyclic peptide derivative, a metallic ion, achromophore, a fluorescent material, a phosphorescent material, aradioactive material, and a catalyst, the method comprising: (a)preparing an affinity chromatography column filled with the compound offormula (1) above bound to a solid phase as a stationary phase; (b)supplying a mixture containing the material bound to a ligand into theaffinity chromatography column; (c) washing the affinity chromatographycolumn with a washing solution; and (d) loading a mobile phase solventinto the affinity chromatography column to separate and purify thematerial bound to the ligand.

According to another aspect of the present invention, there is provideda method of separating and purifying the compound of formula (1) aboveor a material bound to the compound, the material being selected fromthe group consisting of a solid support or a biomolecule, anantioxidant, a chemical therapeutic agent, an anti-histaminic agent, acucurbituril dendrimer, a cyclodextrin derivative, a crown etherderivative, a calixarene derivative, a cyclophane derivative, a cyclicpeptide derivative, a metallic ion, a chromophore, a fluorescentmaterial, a phosphorescent material, a radioactive material, and acatalyst, the method comprising: (a) preparing an affinitychromatography column filled with a ligand bound to a solid phase as astationary phase; (b) supplying a mixture containing the compound offormula (1) or the material bound to the compound into the affinitychromatography column; (c) washing the affinity chromatography columnwith a washing solution; and (d) loading a mobile phase solvent into theaffinity chromatography column to separate and purify the compound offormula (1) or the material bound to the ligand.

According to another aspect of the present invention, there is provideda sensor chip comprising a compound of formula (1) above bound to afirst material and a ligand bound to a second material, wherein one ofthe first and second materials is a solid phase, and the other isselected from the group consisting of an enzyme including histidine,cystein, or tryptophane, a substrate, a substrate analogue, asuppressor, a coenzyme, an antibody, an antigen, a virus, cell lectin, apolysaccharide, a glucoprotein, a cell surface receptor, a nucleic acid,a complementary base sequence, histone, a nucleic acid polymerase, anucleic acid binding protein, ATP, ADP, a hormone, a vitamine, areceptor, a carrier protein, glutathione, a GST fusion protein, ametallic ion, a polyHIS fusion protein, a natural protein, and acombination thereof.

According to another aspect of the present invention, there is provideda solid-catalyst complex comprising the compound of formula (1) abovebound to a first material and a ligand bound to a second material,wherein one of the first and second materials is a solid phase, and theother is a catalyst.

BRIEF DESCRIPTION OF THE DRAWINGS

The above and other features and advantages of the present inventionwill become more apparent by describing in detail exemplary embodimentsthereof with reference to the attached drawings in which:

FIG. 1 schematically illustrates the non-covalently binding betweencucurbit[7]uril bound to a solid phase and a ligand bound to a solidphase;

FIG. 2 illustrates the reaction of obtaining polystyrene-co-DVB-NCO frompolystyrene-co-DVB-NH₂ and the reaction of immobilizinghydroxycucurbit[7]uril on polystyrene-co-DVB-NCO;

FIGS. 3 and 4 are the FT-IR spectra of polystyrene-co-DVB-NH₂ andpolystyrene-co-DVB-NCO, respectively;

FIG. 5 is the FT-IR spectrum ofpolystyrene-co-DVB-CO-hydroxycucurbit[7]uril obtained by immobilizinghydroxycucurbit[7]uril on polystyrene-co-DVB-NCO;

FIG. 6 illustrates the chloromethylation and dithiol reaction ofCombiGel XE-305;

FIG. 7 is the FT-IR spectrum of CombiGel XE-305;

FIG. 8 is the FT-IR spectrum of chloromethylated CombiGel XE-305;

FIG. 9 is the FT-IR spectrum of dithiol-immobilized, chloromethylatedCombiGel XE-305;

FIG. 10 illustrates the reaction of immobilizingalloyloxycucurbit[7]uril onto CombiGel XE-305 that has undergonechloromethylation and dithiol reaction;

FIG. 11 illustrates the reaction of binding of a solid phase toferrocene;

FIG. 12 is the results of electrophoresis on BSA protein purified usinga complex (A) of a hydroxycucurbit[7]uril-bound solid support andferrocene-bound anti-BSA antibody and a complex (B) ofallyloxycucurbit[7]uril-bound solid support and ferrocene-bound anti-BSAantibody;

FIG. 13 is the results of electrophoresis on a lysozyme-containingprotein solution (Lane 2) and a BSA-containing protein solution (Lane 3)purified using a complex of allyloxycucurbituril-bound solid phase andferrocene-bound anti-BSA, in which Lane 1 indicates molecular weightmarkers;

FIG. 14 illustrates the reaction of immobilization ofallyloxycucurbit[7]uril on a gold surface;

FIG. 15 is the FT-IR spectrum of ferrocene methylene trimethylammoniumiodide; FIG. 16 is the FT-IR spectrum of allyloxycucurbit[7]uril boundto a surface of a gold electrode;

FIG. 17 is the FT-IR spectrum of ferrocene methylene trimethyl ammoniumiodide trapped in allyloxycucurbituril[7] molecules bound to the surfaceof the gold electrode;

FIG. 18 is the UV-Vis absorption spectrum of o-dianisidine. 2HCl showingthe activity of a sensor in which a glucose oxidase is bound tocucurbit[7]uril and ferrocene;

FIG. 19 is a calibration curve of glucose concentration in a range of10-120 mM obtained using the sensor in which the glucose oxidase isbound to cucurbit[7]uril and ferrocene;

FIG. 20 is the results of flow cytometry showing the fluorescentintensity of fluoresceine isothiocyanate (FITC) in KB cells (a)untreated with doxorubicin and KB cells (b) treated with doxorubicin,both KB cells (a) and (b) being treated with an annexin V-ferrocenederivative and then a FITC-cucurbituril derivative before the flowcymetry; and

FIG. 21 is the IR spectrum of the adamantylaminated CombiGel XE-305.

DETAILED DESCRIPTION OF THE INVENTION

The inventors have found various applications of cucurbituril based onnon-covalent bonding between the cucurbituril and a specific ligand andcompleted the invention.

Hereinafter, the present invention will be described in detail.

A kit according to the present invention includes: a first componentthat is a compound of formula (1) bound to a first material; and asecond component that is a ligand bound to a second material.

The compound (cucurbituril derivative) of formula (1) of the firstcomponent and the ligand of the second component form a non-covalentbond as the ligand is inserted into a cavity of the cucurbiturilderivative of formula (1).

Each of the first and second materials can be a solid phase as a solidsupport and a material having a particular function, such as a probematerial, selected from the group consisting of a biomolecule, anantioxidant, a chemical therapeutic agent, an anti-histaminic agent, acucurbituril dendrimer, a cyclodextrin derivative, a crown etherderivative, a calixarene derivative, a cyclophane derivative, a cyclicpeptide derivative, a metallic ion, a chromophore, a fluorescentmaterial, a phosphor, a radioactive material, and a catalyst.

In the kit according to the present invention, one of the first andsecond materials may be a biomolecule, and the other may be achromophore, a fluorescent material, or a phosphor. This kit can be usedto detect a particular material that can bind to or react with thebiomolecule and further to detect the presence, position, or amount ofthe particular material, etc. For example, such a kit can be used invarious analysis methods, for example, immunochemical staining, flowcytometry, in-situ hybridization, etc., based on the binding forcebetween the compound of formula (1) of the first component and theligand of the second component.

The solid phase that can be used as the first or second material in thekit according to the present invention may be a solid support selectedfrom the group consisting of a polymer, a resin, a magnetic material, asilicagel, a polymer- or gold-coated silicagel, a zirconium oxide, amonolithic polymer, a polymer-coated magnetic particle, a gold thinfilm, a silver thin film, glass, an ITO-coated glass, silicon, a metalelectrode, a nanorod, a nanotube, a nanowire, curdlan gum, cellulose, anylon film, sepharose, and sephadex. For example, polystyrene resin orpolymer-coated silicagel can be used as the solid phase.

When a halogen functional group (preferably, chloro group) exist on thesurface of the solid phase, the halogen function group forms a covalentbond by the reaction with a functional group (for example, amine group)in the cucurbituril derivative or the ligand. As a result, the solidphase and the cucurbituril derivative or the ligand can be boundtogether.

Examples of the biomolecule that can be used as the first or secondmaterial in the kit according to the present invention include anenzyme, a nucleic acid, a protein, an amino acid, an antibody, anantigen, an inhibitor, a vitamin, a cofactor, a fatty acid, a cell, acell membrane, a substrate, a substrate analogue, a suppressor, acoenzyme, a virus, lectin, a polysaccharide, a glucoprotein, a receptor,histone, ATP, ADP, a hormone, a receptor, glutathione, etc.

Examples of the enzyme, but are not limited to, include cellulase,hemicellulase, peroxidase, protease, amylase, xylanase, lipase,esterase, cutinase, pectinase, keratinase, reductase, oxidase,phenoloxidase, lipoxigenase, ligninase, pullulanase, arabinosidase,hyaluronidase, a combination thereof, etc.

Examples of the catalyst include, but are not limited to, a Grubbscatalyst, a radical initiator, a combination thereof, etc.

In an embodiment of the present invention, the compound of formula (1)may have an additional functional group. The functional group can be,for example, an amine group, a carboxyl group, etc., such as(aminoethylsulfanyl)propyl, (carboxyethylsulfanyl)propyl, etc.

In formula (1) above of the compound, which is a cucurbiturilderivative, each of A₁ and A₂ can be independently H, OR, SR, or NHRwhere R is a substituted or non-substituted C₂-C₃₀ alkenyl group.

In formula (1) above, n may be 7, and X may be O.

The cucurbituril derivative, which is the compound of formula (1) of thefirst component and a particular ligand of the second component, whichare included in the kit according to the present invention, bindtogether depending on pH. In particular, the cucurbituril derivative andthe ligand form a complex in an acidic condition, whereas the complexdissociates in a basic condition. The cucurbituril derivative and theligand non-covalently bind together in an acid solution of pH 8 or lesswith a binding constant of about 10¹⁰-10¹⁵ M⁻¹, and maintain adissociated state in an alkali solution of pH 8 or greater with abinding constant of about 10⁰-10⁴ M⁻¹. The binding constant between thecucurbituril derivative and the ligand increases as the pH decreases,whereas the binding constant decreases as the pH increases and thesolution changes to alkali A cucurbituril derivative that is thecompound of formula (1) of the first component and a particular ligandof the second component can non-covalently bind together with a bindingconstant of about 10⁰-10¹⁵ M⁻¹ according to the pH of a reactionsolution. For example, a cucurbituril derivative with n=7 and anadamantane amine or ferrocene methylamine ligand can non-covalently bindtogether with a binding constant of about 10¹² M⁻¹ or greater at pH 8 orless, and remain in a dissociated state with a binding constant of about10⁴ M⁻¹ or less at pH 8 or greater.

When the binding constant between the cucurbituril derivative that isthe compound of formula (1) of the first component and the particularligand of the second component is 10⁴ M⁻¹ or less, their bond is weakand dissociates when a mobile solvent is flowed. When the bindingconstant is greater than 10¹⁰ M⁻¹, their bond is strong and unlikelydissociates.

In the kit according to the present invention, the ligand of the secondcomponent, which can non-covalently bind to the cucurbituril derivative,i.e., the compound of formula (1) of the first component may have atleast one amine group and be selected from the group consisting of aC₁-C₂₀ alkyl group; a C₂-C₂₀ alkenyl group; a C₂-C₂₀ alkynyl group; aC₁-C₂₀ alkoxy group; a C₁-C₂₀ aminoalkyl group; a C₄-C₂₀ cycloalkylgroup; a C₄-C₇ heteroarylcyclo group; a C₆-C₂₀ aryl group; a C₅-C₂₀heteroaryl group; a C₁-C₂₀ alkylsilyl group; a C₆-C₂₀ aryl group; aC₅-C₂₀ heteroaryl group; adamantane having a substituted ornon-substituted C₁-C₂₀ alkyl group, C₆-C₂₀ aryl group or C₅-C₂₀heteroaryl group; ferrocene or metallocene having a substituted ornon-substituted C₁-C₂₀ alkyl group, C₆-C₂₀ aryl group or C₅-C₂₀heteroaryl group; carborane having a substituted or non-substitutedC₁-C₂₀ alkyl group, C₆-C₂₀ aryl group or C₅-C₂₀ heteroaryl group;fullerene having a substituted or non-substituted C₁-C₂₀ alkyl group,C₆-C₂₀ aryl group or C₅-C₂₀ heteroaryl group; cyclam or crown etherhaving a substituted or non-substituted C₁-C₂₀ alkyl group, C₆-C₂₀ arylgroup or C₅-C₂₀ heteroaryl group; an oxygen-protected amino acid havinga substituted or non-substituted C₁-C₂₀ alkyl group, C₆-C₂₀ aryl groupor C₅-C₂₀ heteroaryl group; peptide having a substituted ornon-substituted C₁-C₂₀ alkyl group, C₆-C₂₀ aryl group or C₅-C₂₀heteroaryl group; alkaloid having a substituted or non-substitutedC₁-C₂₀ alkyl group, C₆-C₂₀ aryl group or C₅-C₂₀ heteroaryl group;cisplatin having a substituted or non-substituted C₁-C₂₀ alkyl group,C₆-C₂₀ aryl group or C₅-C₂₀ heteroaryl group; oligonucleotide having asubstituted or non-substituted C₁-C₂₀ alkyl group, C₆-C₂₀ aryl group orC₅-C₂₀ heteroaryl group; rhodamine having a substituted ornon-substituted C₁-C₂₀ alkyl group, C₆-C₂₀ aryl group or C₅-C₂₀heteroaryl group; and a nanoparticle having a substituted ornon-substituted C₁-C₂₀ alkyl group, C₆-C₂₀ aryl group or C₅-C₂₀heteroaryl group,

For example, the ligand can be adamantane, ferrocene, or metallocenethat have at least one amine group and a substituted or non-substitutedC₁-C₂₀ alkyl group, C₆-C₂₀ aryl group or C₅-C₂₀ heteroaryl group. Theamine group may be a primary amine, a secondary amine, or a hydrogenatedamine. For example, the ligand can be adamantanamine or ferrocenemethylamine.

According to the present invention, a material bound to a ligand can beseparated or purified using the non-covalent binding between acucurbituril derivative and the ligand.

According to another aspect of the present invention, there is provideda method of separating and purifying a material bound to a ligand, thematerial being selected from the group consisting of a biomolecule, anantioxidant, a chemical therapeutic agent, an anti-histaminic agent, acucurbituril dendrimer, a cyclodextrin derivative, a crown etherderivative, a calixarene derivative, a cyclophane derivative, a cyclicpeptide derivative, a metallic ion, a chromophore, a fluorescentmaterial, a phosphor, a radioactive material, and a catalyst, the methodcomprising: (a) preparing an affinity chromatography column filled witha compound of formula (1) bound to a solid phase as a stationary phase;(b) supplying a mixture containing the material bound to a ligand intothe affinity chromatography column; (c) washing the affinitychromatography column with a washing solution; and (d) loading a mobilephase solvent into the affinity chromatography column to separate andpurify the material bound to the ligand.

The affinity chromatography column used in the method can be any columncommonly used in the field.

Examples of the biomolecule that can be used in the method according tothe present invention include an enzyme, a nucleic acid, a protein, anamino acid, an antibody, an antigen, an inhibitor, a vitamin, acofactor, a fatty acid, a cell, a cell membrane, a substrate, asubstrate analogue, a suppressor, a coenzyme, a virus, lectin, apolysaccharide, a glucoprotein, a receptor, histone, ATP, ADP, ahormone, a receptor, glutathione, etc. Examples of the enzyme includecellulase, hemicellulase, peroxidase, protease, amylase, xylanase,lipase, esterase, cutinase, pectinase, keratinase, reductase, oxidase,phenoloxidase, lipoxigenase, ligninase, pullulanase, arabinosidase,hyaluronidase, a combination thereof, etc.

The ligand that can be used in the method of separating and purifying amaterial bound to the ligand can non-covalently bind to the compound offormula (1) and has at least one amine group. Such a ligand is selectedfrom the group consisting of a C1-C20 alkyl group; a C2-C20 alkenylgroup; a C2-C20 alkynyl group; a C1-C20 alkoxy group; a C1-C20aminoalkyl group; a C4-C20 cycloalkyl group; a C4-C7 heteroarylcyclogroup; a C6-C20 aryl group; a C5-C20 heteroaryl group; a C1-C20alkylsilyl group; a C6-C20 aryl group; a C5-C20 heteroaryl group;adamantane having a substituted or non-substituted C1-C20 alkyl group,C6-C20 aryl group or C5-C20 heteroaryl group; ferrocene or metallocenehaving a substituted or non-substituted C1-C20 alkyl group, C6-C20 arylgroup or C5-C20 heteroaryl group; carborane having a substituted ornon-substituted C1-C20 alkyl group, C6-C20 aryl group or C5-C20heteroaryl group; fullerene having a substituted or non-substitutedC1-C20 alkyl group, C6-C20 aryl group or C5-C20 heteroaryl group; cyclamor crown ether having a substituted or non-substituted C1-C20 alkylgroup, C6-C20 aryl group or C5-C20 heteroaryl group; an oxygen-protectedamino acid having a substituted or non-substituted C1-C20 alkyl group,C6-C20 aryl group or C5-C20 heteroaryl group; peptide having asubstituted or non-substituted C1-C20 alkyl group, C6-C20 aryl group orC5-C20 heteroaryl group; alkaloid having a substituted ornon-substituted C1-C20 alkyl group, C6-C20 aryl group or C5-C20heteroaryl group; cisplatin having a substituted or non-substitutedC1-C20 alkyl group, C6-C20 aryl group or C5-C20 heteroaryl group;oligonucleotide having a substituted or non-substituted C1-C20 alkylgroup, C6-C20 aryl group or C5-C20 heteroaryl group; rhodamine having asubstituted or non-substituted C1-C20 alkyl group, C6-C20 aryl group orC5-C20 heteroaryl group; and a nanoparticle having a substituted ornon-substituted C1-C20 alkyl group, C6-C20 aryl group or C5-C20heteroaryl group.

The method of separating and purifying a material bound to a ligandaccording to the present invention may further include binding thecompound of formula (1) to the solid phase before operation (a). To thisend, the compound of formula (1) may have an additional functionalgroup. The functional group can be, for example, an amine group, acarboxyl group, etc., such as (aminoethylsulfanyl)propyl,(carboxyethylsulfanyl)propyl, etc.

The method of separating and purifying a material bound to a ligand mayfurther include binding the ligand and the material between operations(a) and (b).

The compound of formula (1) and the solid phase, or the ligand and thesolid phase may be covalently bound together.

Examples of the mobile solvent that can be used in the method ofseparating and purifying a material bound to a ligand according to thepresent invention include methanol, trifluoracetic acid, triethylamine,methylene chloride, chloroform, dimethylformamide, dimethyl sulfoxide,toluene, acetonitrile, xylene, chlorobenzine, tetrahydrofurane,diethylether, ethanol, diglycol ether, silicon, supercritical carbondioxide, ionic liquids, N-methylpyrrolidine, pyridine, water, ammoniumhydroxide, dioxane, etc.

Examples of the washing solution that can be used in the method ofseparating and purifying a material bound to a ligand according to thepresent invention include methanol, trifluoracetic acid, triethylamine,methylene chloride, chloroform, dimethylformamide, dimethyl sulfoxide,toluene, acetonitrile, xylene, chlorobenzine, tetrahydrofurane,diethylether, ethanol, diglycol ether, silicon, supercritical carbondioxide, ionic liquids, N-methylpyrrolidine, pyridine, water, ammoniumhydroxide, dioxane, etc.

The present invention also provides a method of separating and purifyinga compound of formula (1) or a material bound to the compound, thematerial being selected from the group consisting of a biomolecule, anantioxidant, a chemical therapeutic agent, an anti-histaminic agent, acucurbituril dendrimer, a cyclodextrin derivative, a crown etherderivative, a calixarene derivative, a cyclophane derivative, a cyclicpeptide derivative, a metallic ion, a chromophore, a fluorescentmaterial, a phosphor, a radioactive material, and a catalyst, the methodcomprising: (a) preparing an affinity chromatography column filled witha ligand bound to a solid phase as a stationary phase; (b) supplying amixture containing the compound of formula (1) or the material bound tothe compound into the affinity chromatography column; (c) washing theaffinity chromatography column with a washing solution; and (d) loadinga mobile phase solvent into the affinity chromatography column toseparate and purify the compound of formula (1) or the material bound tothe ligand,

The method of separating and purifying the compound of formula (1) or amaterial bound to the compound may further include binding the ligand tothe solid phase before operation (a).

When separating and purifying a material bound to the compound offormula (1), the method may further include binding the compound offormula (1) and the material between operations (a) and (b). To thisend, the compound of formula (1) may have an additional functionalgroup. The functional group can be, for example, an amine group, acarboxyl group, etc., such as (aminoethylsulfanyl)propy,(carboxyethylsulfanyl)propyl, etc.

The washing solution and the mobile phase solvent used in the method ofseparating and purifying the compound of formula (1) or a material boundto the compound according to the present invention may be the same asused in the method of separating and purifying a material bound to theligand described above.

When an additional purification process, such as dialysis, etc., isperformed on a solution recovered from the column in the above-describedseparating and purifying method, a higher purity material can beobtained.

The cucurbituril derivative of formula (1) bound to a solid phase or aparticular material form a stable complex with a ligand bound to a solidphase or a particular material with a strong binding force that remainsafter the removal of a solvent. Whether the cucurbituril derivative offormula (1) and a ligand can bind together depends on the type ofsolvent, pH, polarity, temperature, and electrical change.

In order to induce the binding of the cucurbituril derivative of formula(1) and the ligand, a condition allowing the hydrogenation of the aminegroup of the ligand or an acidic condition is required. In order todissociate the bind of the cucurbituril derivative and the ligand, adehydrogeneration condition or an alkali condition is required.

According to the present invention, a material can be separated orpurified using the non-covalent bonding between the compound of formula(1) and a ligand. In particular, a particular component bound to aligand in a mixture can be separated or purified using the compound offormula (1) bound to a solid phase. In addition, the compound of formula(1) in a mixture or a particular compound bound to the compound offormula (1) can be separated using a ligand bound to a solid phase.

In particular, a method of using a magnetic material (magnet) for thesolid phase, a method of using a filter, etc., can be used to easilyseparate such a particular component as described above.

Further, when an additional dialysis process, etc., is performed afterthe method of using a magnet or filter, a higher purity material can beobtained.

In the method of using a magnet or filter, methanol, trifluoraceticacid, triethylamine, methylene chloride, chloroform, dimethylformamide,dimethyl sulfoxide, toluene, acetonitrile, xylene, chlorobenzine,tetrahydrofurane, diethylether, ethanol, diglycol ether, silicon,supercritical carbon dioxide, ionic liquids, N-methylpyrrolidine,pyridine, water, ammonium hydroxide, dioxane, etc., can be used as asolvent.

According to another aspect of the present invention, there is provideda sensor chip comprising a complex of the compound of formula (1) boundto a first material and a ligand bound to a second material.

Sensor chips are devices with a probe material (for example,biomolecule, etc.) on a solid substrate to detect a target material.

In the sensor chip according to the present invention, one of the firstand second materials is a solid phase, and the other is a probematerial.

In the sensor chip according to the present invention, the solid phasethat can be used as the first or second material may be a solid support,such as a gold thin film, a silver thin film, or an ITO-coated glass.

Examples of the probe materials that can be used as the first or secondmaterial include, but are not limited to, an enzyme, such as histidine,cystein, or tryptophane, a substrate, a substrate analogue, asuppressor, a coenzyme, an antibody, an antigen, a virus, cell lectin, apolysaccharide, a glucoprotein, a cell surface receptor, a nucleic acid,a complementary base sequence, histone, a nucleic acid polymerase, anucleic acid binding protein, ATP, ADP, a hormone, a vitamine, areceptor, a carrier protein, glutathione, a GST fusion protein, ametallic ion, a polyHIS fusion protein, a natural protein, a combinationthereof, etc. Examples of the enzyme include cellulase, hemicellulase,peroxidase, protease, amylase, xylanase, lipase, esterase, cutinase,pectinase, keratinase, reductase, oxidase, phenoloxidase, lipoxigenase,ligninase, pullulanase, arabinosidase, hyaluronidase, a combinationthereof, etc.

The sensor chip according to the present invention can confirm thedetection of a target material through an electrochemical method, anoptochemical method, a fluorescent method, a phosphorescent method,HPLC, gas chromatography, NMR, EPR, an isotropic method, etc.

The sensor chip according to the present invention can be used as abiosensor or bio-fuel cell electrode when the probe material is abiomolecule.

According to another aspect of the present invention, there is provideda solid-catalyst complex comprising a compound of formula (1) belowbound to a first material and a ligand bound to a second material,wherein one of the first and second materials is a solid phase, and theother is a catalyst.

In the solid-catalyst complex according to the present invention, thecatalyst may be a Grubbs catalyst, a radical initiator, or a combinationthereof.

In the solid-catalyst complex according to the present invention, thecatalyst may be selected from the group consisting of cellulase,hemicellulase, peroxidase, protease, amylase, xylanase, lipase,esterase, cutinase, pectinase, keratinase, reductase, oxidase,phenoloxidase, lipoxigenase, ligninase, pullulanase, arabinosidase,hyaluronidase, and a combination thereof.

Examples of the solid phase that can be used in the solid-catalystcomplex according to the present invention include a polymer, a resin, amagnetic material, a silicagel, a polymer- or gold-coated silicagel, azirconium oxide, a monolithic polymer, a polymer-coated magneticparticle, a gold thin film, a silver thin film, glass, an ITO-coatedglass, silicon, a metal electrode, a nanorod, a nanotube, a nanowire,curdlan gum, cellulose, a nylon film, sepharose, sephadex, etc. Inparticular, the solid phase can be polystyrene resin or polymer-coatedsilicagel.

The solid-catalyst complex according to the present invention can berepeatedly used unlit the catalytic activity disappears and provides acatalytic function through an organic reaction at room temperature. Fora catalytic function, various buffer solutions suitable for reactionscan be used. Examples of buffer solutions that can be used includemethanol, trifluoracetic acid, triethylamine, methylene chloride,chloroform, dimethylformamide, dimethyl sulfoxide, toluene,acetonitrile, xylene, chlorobenzine, tetrahydrofurane, diethylether,ethanol, diglycol ether, silicon, supercritical carbon dioxide, ionicliquids, N-methylpyrrolidine, pyridine, water, ammonium hydroxide,dioxane, etc.

Whether a cucurbituril derivative and a ligand respectively bound toparticular materials have bound together can be conformed throughFourier Transform Infrared (FT-IR) absorption measurement.

Hereinafter, the present invention will be described in greater detailwith reference to the following examples. The following examples areonly for illustrative purposes and are not intended to limit the scopeof the invention.

EXAMPLE 1 Synthesis of Cucurbit[7]uril

After melting glycouryl (5.7 g, 40 mmol) in 20 mL of sulfuric acid (9M), an aqueous formaldehyde solution (7.0 mL, 91 mmol) was added. Theresultant reaction mixture was stirred at 75 □ for 24 hours. Thetemperature was raised to 95-100□, and the reaction was furtherperformed. 200 mL of water was quickly poured into the reaction mixture,and 1 L of acetone was further added to obtain a precipitate. Theprecipitate was filtered under reduced pressure and washed with a 1:4mixed solution of water and acetone. The solid filtrate was dissolved in200 mL of a 1:1 mixed solution of water and acetone and filtered underreduced pressure to remove a precipitate (cucurbit[6]uril).

800 mL of acetone was added to the filtrate to precipitate a mixture ofcucurbit[7]uril and cucurbit[5]uril. The precipitated mixture ofcucurbit[7]uril and cucurbit[5]uril was dissolved in 40 mL of water, and25 mL of methanol was added to precipitate only cucurbit[7]uril. Theprecipitated cucurbit[7]uril was filtered under reduced pressure anddried in a vacuum. The results of an analysis are as follows.

¹H NMR (500 MHz, D₂O): δ=5.56 (d, 14H), 5.35 (s, 14H), 4.11 (d, 14H).

EXAMPLE 2 Synthesis of Hydroxycucurbit[7]uril

Cucurbit[7]uril (10 g, 8.6 mmol) synthesized in Example 1 and K₂S₂O₈ (39g, 145 mmol) were added to 450 mL of distilled water and subjected toultrasonication for 10 minutes. Next, the temperature was raised to 85°C., and the reaction was performed for 12 hours. The reaction mixturewas cooled to room temperature to obtain a white precipitate. Theprecipitate was removed through filtration under reduced pressure. Asolvent in the filtrate was vaporized to obtain hydroxycucurbit[7]uril.The degree of substitution of hydroxycucurbit[7]uril was about 0.8. Thedegree of substitution of hydroxycucurbit[7]uril refers to the ratio ofsubstitution of hydrogen (A₁ and A₂ in formula 1) in cucurbit[7]uril byhydroxyl groups.

¹H-NMR (500 MHz, DMSO-d₆): δ=7.83 (s, 11H), 5.68-5.12 (d, 17H), 4.42 (d,14H);

¹³C-NMR (125 MHz, DMSO-d₆): δ=152.7, 93.8, 40.2.

EXAMPLE 3 Synthesis of Allyloxycucurbit[7]uril

Hydroxycucurbit[7]uril (1.2 g, 0.92 mmol) synthesized in Example 2 wasadded into an anhydrous DMSO solution (150 mL) and dissolved. NaH (0.89g, 22.4 mmol) was added into the solution. The reaction mixture wasstirred in an argon atmosphere at room temperature for 1 hour, and arylbromide (2.0 mL, 22.0 mmol) was slowly added into the reaction mixtureat 0° C. while stirring. After the reaction mixture was further stirredat room temperature for 12 hours, an excess of water was added into thereaction mixture to precipitate allyloxycucurbit[7]uril. The degree ofsubstitution of the obtained allyloxycucurbit[7]uril was about 0.7.

EXAMPLE 4 Synthesis of Solid-Phase (Polystyrene-co-DVD-NCO)

After amine-functionalized polystyrene-co-divinylbenzene(polystyrene-co-DVB-NH₂, Aldrich Corp., 30-60 mesh, 2.5 mmol N/g, 5.0 g,12.5 mmol or 30) as a polymeric resin was added into 50 mL ofdichloromethane, triethylamine (9.6 mL, 69 mmol) and triphosgen (2.7 g,9.1 mmol) were added into the mixture and shaken at room temperature for36 hours. After filtration under reduced pressure, the resulting filtercake was washed with dichloromethane, chloroform, ether, and thentetrahydrofurane and dried in a vacuum dried for 24 hours to obtainisocyanatemethyl polystyrene-co-divinylbenzene (polystyrene-co-DVB-NCO),polymeric resin with an isocyanate group substituted for the amine group(FIG. 2).

Comparing the IR spectrum of polystyrene-co-DVB-NH₂ of FIG. 3 and the IRspectrum of polystyrene-co-DVB-NCO of FIG. 4, a new peak of theisocyanate group (—NCO) appears near 2264 cm⁻¹ in the IR spectrum ofFIG. 4.

The results of measuring the IR spectrum of polystyrene-co-DVB-NCO inFIG. 4 are as follows.

IR (KBr): 3027, 2929, 2264, 1659, 1602, 1494, 1452, 1269, 1116, 1029cm⁻¹

EXAMPLE 5 Immobilization of Hydroxycucurbit[7]uril onto Solid-Phase

After the solid-phase polystyrene-co-DVB-NCO polymer resin (2.0 g, 2.5mmol N/g) obtained in Example 4 was swelled with 8 mL of dimethylsulfuroxide, a solution of the hydroxycucurbit[7]uril (1.44 g, 1.2 mmol)obtained in Example 2 in a mixture of dimethyl sulfuroxide/pyridine (37mL/3 mL) was added and stirred at 60° C. in an argon environment for 120hours to be uniformly mixed (FIG. 2). Next, the reaction mixture wasfiltered under reduced pressure, washed several times with dimethylsulfoxide, methanol, water, and ether, and dried at 50° C. in a vacuumfor 24 hours to immobilize hydroxycucurbit[7]uril onto the solid-phase.The results of measuring the IR spectrum of the immobilizedhydroxycucurbit[7]uril are as follows (refer to FIG. 5)

IR (KBr): 3026, 2920, 1755, 1689, 1602, 1493, 1452, 1272, 1115, 1028cm⁻¹.

Referring to FIG. 5, the peak of isocyanate group near 2264 cm⁻¹ in FIG.4 disappears, and a new peak of carbonyl carbon in thehydroxycucurbit[7]uril appears at 1755 cm⁻¹. In addition, it wasconfirmed through an element analysis that 75-110 μmol ofhydroxycucurbit[7]uril per 1 g of the solid phase had been immobilized.

EXAMPLE 6 Preparation of Solid-Phase

(1) Chloromethylation of Porous Polystyrene (Cross-Linked with 1%Divinylbenzene)

After 3 g of porous polystyrene CombiGel XE-305 (Aldrich Corp.)(cross-linked with 1% divinylbenzene) was mixed with chloromethylmethylether (29.90 g, 0.38 mmol), SnCl₄ (0.90 mL) was dropwise addedinto the mixture at 0° C. The reaction mixture was refluxed at 59° C.for 4.5 hours. The colorless CombiGel XE-305 gradually changed red. Amethanol solution was added to neutralize the reaction mixture until thered color disappeared. The polymeric resin was filtered through a glassfilter with methanol, tetrahydrofurane (THF), and water to obtainchloromethylated polystyrene (cross-linked with 1% divinylbenzene) inwhite powder form. The results of an element analysis are as follows.

Element analysis: C, 68.68; H, 6.01; Cl, 18.35%

As is apparent from the results of the element analysis, 5.2 mmol ofchlorine exists per 1 g of chloromethylated polystyrene (cross-linkedwith 1% divinylbenzene).

Comparing the IR spectrum of CombiGel XE-305 in FIG. 7 and the IRspectrum of chloromethylated CombiGel XE-305 in FIG. 8, an absorptionpeak near 1265 cm⁻¹, not seen in the IR spectrum of FIG. 7, appears inthe IR spectrum of FIG. 8. The absorption peak near 1265 cm⁻¹corresponds to —C—Cl.

The results of the IR spectrum of the chloromethylated polystyrene inFIG. 8 are as follows.

IR spectrum: 2928, 1725, 1612, 1510, 1445, 1422, 1265 cm⁻¹.

(2) Immobilization of Dithiol onto Chloromethylated Polystyrene(Cross-Linked with 1% Divinylbenzene)

2.0 g of the chloromethylated polystyrene (cross-linked with 1%divinylbenzene) obtained in (1) was swelled with 20 mL of toluene.Propane-1,3-dithiol (2 mL, 20 mmol) was added and gently shaken for 15minutes. 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) (0.9 mL, 6 mmol) wasdropwise added into the reaction mixture and stirred at room temperaturefor 24 hours (FIG. 6). The resulting resin was filtered under reducedpressure and washed with dimethylformamide (DMF) and then CH₂Cl₂. Thewashed resin was dried in a vacuum for 12 hours to immobilize dithiolonto the chloromethylated CombiGel XE-305. As a result of an elementanalysis, the degree of immobilization of thiol groups was 1.9 mmol/g(per 1 g of the solid phase).

IR spectrum: 2918, 2850, 2563, 1727, 1509, 1423, 1238 cm⁻¹

Referring to the IR spectrum of FIG. 9, a stretching peak of —SH appearsnear 2563 cm⁻¹.

EXAMPLE 7 Immobilization of Allyloxycucurbit[7]uril onto Solid Phase

1.5 g of the dithiol-immobilized polystyrene (cross-linked with 1%divinylbenzene) obtained in Example 6 and 1.1 g (0.68 mmol) ofallyloxycucurbit[7]uril obtained in Example 3 were added to 16 mL ofmethanol and irradiated with 300 nm UV rays in an argon environment for120 hours (5 days) (refer to FIG. 10). After termination of thereaction, the allyloxycucurbit[7]uril-bound polymer resin was filteredunder reduced pressure, washed with methanol, chloroform, acetone, andthen ether, and dried in a vacuum for 12 hours.

IR Spectrum: 2917, 2852, 1753, 1725, 1510, 1425, 1238 cm⁻¹.

A peak of carbonyl groups in cucurbit[7]uril appeared near 1753 cm⁻¹ inthe IR spectrum. As a result of an element analysis, it was confirmedthat 80-115 μmol of allyloxycucurbit[7]uril per 1 g of the solid phasewas immobilized.

EXAMPLE 8 Binding of Ligand (Ferrocene Derivative) and Protein (BovineSerum Albumin)

(1) Synthesis of (N-(ferrocenylmethyl)-6-aminocaproic acid (Fc-aca)

After 1.38 g (6.4 mmol) of ferrocene-aldehyde (Aldrich Corp) wasdissolved in 20 mL of a DMF solution, the mixture was mixed with asolution of 0.75 g (5.7 mmol) of 6-amino caproic acid (Merck Corp.) in 5mL of NaOH and refluxed at 80° C. for 2 hours. The reaction mixture wascooled to room temperature, and a solution of NaBH₄ (0.63 g, 16.5 mmol)in 5 mL of water was added little by little into the reaction mixture(refer to FIG. 11). After 12 hours later, an aqueous acetic acidsolution (10%) was slowly added until the pH reached 5. The reactionby-product ferrocene-CH₂OH and unreacted 6-amino caproic acid dissolvedin the organic phase was removed through extraction using ethylacetate.The aqueous phase was distilled at 50° C. under reduced pressure toobtain yellowish brown crystals. The yellowish brown crystals wererecrystallized by dissolving the crystals in high-temperature ethanol toobtain planar, yellow crystalline N-(ferrocenyl methyl)-6-amino caproicacid.

The N-(ferrocenyl methyl)-6-amino caproic acid was identified throughHPLC, ¹H-NMR, and mass analysis. The recrystallized product wasseparated with a high purity through HPLC. The ¹H-NMR spectrum ofN-(ferrocenyl methyl)-6-amino caproic acid is as follows.

¹H-NMR (D₂O, 300 MHz): δ=4.05-4.43 (9H, m, ferrocene ring protons), 3.46(2H, s, CH₂), 2.49 (2H, t, CH₂), 1.36 (6H, m, CH₂), 2.02 (2H,t CH₂).

As a result of a mass analysis, a molecular peak at m/e=330 (Fc-acaH⁺)appeared.

(2) Binding of N-(ferrocenyl methyl)-6-amino caproic acid (Fc-aca) andbovine serum albumin (BSA)

15 mg of the N-(ferrocenyl methyl)-6-amino caproic acid (Fc-aca)obtained in (1), 6 mg of N-hydrosucciinimide (NHS, Fluka Corp.), and 9mg of N-(3-dimethylaminopropyl)-N-ethylcarbodiimide hydrochloride (EDC,Fluka Corp.) were dissolved in 0.3 mL of an anhydrous DMF solution.After the temperature was raised to 90° C. in a nitrogen atmosphere, themixture was stirred for 30 minutes (refer to FIG. 11). The reaction wasfurther performed for 30 minutes while the temperature of the solutionwas maintained at 80° C. Next, the temperature was cooled to roomtemperature. 30 μL of the reaction mixture was added into a solution of7 mg of bovine serum albumin in 1 mL of phosphate buffer solution (100mM) at 2-minute intervals. The mixture was shaken at room temperaturefor a day and centrifuged to separate a precipitate. The filtrate wasdialyzed in a 50 mM phosphate buffer solution (pH 7.4) for 30 hours toobtain a N-(ferrocenyl methyl)-6-amino caproic acid (Fc-aca)-boundbovine serum albumin (ferrocene-bound BSA).

EXAMPLE 9 Purification of Protein

The ferrocene derivative-bound BSA was purified using thehydroxycucurbit[7]uril-bound solid phase obtained in Example 5.

1.5 g of the hydroxycucurbit[7]uril-immobilized solid phase obtained inExample 5 was put into a 10-mL disposable syringe, and 40 mL of CH₂Cl₂was continuously flowed at a rate of 1.3 mL/min. Next, the solid phasewas washed with 50 mL of DMF at a rate of 0.7 mL/min.

2 mg of the ferrocene derivative-bound BSA obtained in Example 8, 1 mgof a glucose oxidase, and 1 mg of a lipase were dissolved in a 0.1 MHEPES buffer solution (pH 6.0) to obtain a protein mixture.

Next, after the protein mixture was slowly flowed into the disposablesyringe at a rate of 0.7 mL/min, the syringe was washed with 50 mL ofwater at a rate of 2 mL/min and then DMF/TEA (40 mL/20 mL) at a rate of2 mL/min.

Next, 60 mL of a HEPES buffer solution (0.1M, pH 8.5) was flowed at arate of 2 mL/min to recover an eluate from the syringe.

After the recovered eluate was processed at 60° C. to denaturizeprotein, Coomassie blue was added into 150 μL of the eluate, loaded ontoa SDS-PAGE, and subjected to electrophoresis at 10 mA for 5 hours. Atthis time, molecular weight markers were simultaneously loaded onto theSDS-PAGE.

Next, the SDS-PAGE gel was separated from the electrophoretic apparatus,washed, dipped in Coomassie blue for 1 hour, and washed with a washingsolution overnight.

The degree of staining of the gel was measured using a gel scanner. Theresults are shown in A of FIG. 12. Lane 1 in A of FIG. 12 representsmolecular weight markers, and Lane 2 is the results of staining obtainedby loading the eluate.

As a result, a single band of 66 kDa appears in Lane 2, indicating thatthe hydroxycucurbituril-immobilized solid phase can separate and purifyferrocene-bound BSA from the protein mixture.

The eluate was freeze-dried to obtain a pure ferrocene derivative-boundBSA protein.

EXAMPLE 10 Purification of Protein

In this example, a cucurbituril-conjugated protein was purified using aferrocene-bound solid phase.

(1) Ferrocene Methylamination of Chloromethylated Solid Phase

1.5 g of chloromethylated Combigel XE-305 obtained in (1) of Example 6was swelled in 14 mL of DMF for 2 hours. The chloromethylated CombigelXE-305 in DMF was added into a DMF-pyridine (1:2 v/v, 9.0 mL) solutionin which ferrocene methylamine (1.35 g, 6.3 mmol) was dissolved andstirred at 55° C. for 43 hours. The reaction mixture was filtered underreduced pressure, and the filter cake was washed with solvents, i.e.,DMF, CH2Cl2, methanol, and then ether, and dried in a vacuum to obtain aferrocene-methylaminated Combigel XE-305.

Element Analysis: C, 64.52; H, 6.72, N, 5.10%

The results of the element analysis indicate that 3.64 mmol of ferrocenewas bound to 1 g of the ferrocene-methylaminated CombiGel XE-305polymer.

FT-IR: 3419, 3020, 2936, 1627, 1485, 1210, 1151, 1025 cm⁻¹

(2) Synthesis of [3-(2-carboxyethylsulfanyl)propyl-O]₁₄ cucurbit[7]uril

2 mL of DMF was put into a quartz tube. Allyloxycucurbit[7]uril((aryl-O) 14-CB[7], 35 mg, 0.018 mmol) and 3-mercaptopropionic acid (70mL, 0.78 mmol) were added and reacted under UV irradiation (254 nm) for36 hours. Next, DMF was removed through distillation under reducedpressure. The reaction mixture was washed four times with 15 mL ofdiethylether and dried under reduced pressure to obtain 37 mg of[3-(2-carboxyethylsulfanyl)propyl-O]₁₄ cucurbit[7]uril with a yield of60%.

The results of an analysis on the obtained [3-(2-carboxyethylsulfanyl)propyl-O]14cucurbit[7]uril are as follows.

¹H NMR (300 MHz, DMSO-d₆): δ=5.56 (d, J=14.3 Hz, 14H), 4.05 (d, J=14.3Hz, 14H), 3.52 (m, 28H), 2.62 (m, 56H), 2.48 (m, 28H), 1.84 (t, 28H);

¹³C NMR (75 MHz, DMSO): δ=170.0, 151.8, 95.5, 63.2, 40.8, 34.4, 29.2,26.2; MS (MALDI-TOF): m/z 3454.1 [M+Na⁺].

(3) Binding of Cucurbit[7]uril Derivative and Bovine Serum Albumin (BSA)

37 mg of [3-(2-carboxyethyl sulfanyl)propyl-O]₁₄ cucurbit[7]urilobtained in (2), 6 mg of N-hydrosuccinimide (NHS, Fluka Corp.) and 9 mgof N-(3-dimethylaminopropyl)-N-ethylcarbodiimide hydrochloride (EDC,Fluka Corp.) were dissolved in 0.3 mL of an anhydrous DMF solution andstirred for 30 minutes after the temperature was raised to 90□ in anitrogen atmosphere.

The reaction was further performed for 30 minutes while the temperatureof the solution was maintained at 80 □. 30 μL of the reaction mixturewas added into a solution of 7 mg of bovine serum albumin (BSA, SigmaCorp.) in 1 mL of a phosphate buffer solution (100 mM) at 2-minuteintervals. The mixture was shaken at room temperature for a day andcentrifuged to separate a precipitate. The filtrate was dialyzed in a 50mM phosphate buffer solution (pH 7.4) for 30 hours to obtain a3-(2-carboxyethylsulfanyl)propyl-O]₁₄ cucurbit[7]uril-bound bovine serumalbumin. The cucurbit[7]uril-conjugated BSA was purified using theferrocene-methylaminated solid phase obtained in (1).

1.5 g of the ferrocene-methylaminated solid phase was put into a 10-mLdisposable syringe, and 40 mL of CH₂Cl₂ was continuously flowed at arate of 1.3 mL/min. Next, the resin was washed with 50 mL of DMF at aflow rate of 0.7 mL/min.

2 mg of the cucurbit[7]uril-bound BSA, 1 mg of glucose oxidase, and 1 mgof lipase were dissolved in a phosphate buffer solution (0.1M, pH 6.0)to obtain a protein mixture.

Next, after the protein mixture was slowly flowed through a column at arate of 0.7 mL/min, the syringe was washed with 50 mL of water at a flowrate of 2 mL/min and then DMF/TEA (40 mL/20 mL) at a flow rate of 2mL/min.

Next, 60 mL of a HEPES buffer solution (0.1M, pH 8.5) was flowed at arate of 2 mL/min to recover an eluate from the syringe. After therecovered eluate was processed at 60° C. to denaturize protein,Coomassie blue was added into 150 μL of the eluate, loaded onto aSDS-PAGE, and subjected to electrophoresis at 10 mA for 5 hours. At thistime, molecular weight markers were simultaneously loaded onto theSDS-PAGE.

The degree of staining of the gel was measured using a gel scanner. Theresults are shown in B of FIG. 12. Lane 1 in B of FIG. 12 representsmolecular weight markers, and Lane 2 is the results of staining obtainedby loading the eluate.

As a result, a single band of 66 kDa appears in Lane 2, indicating thatthe ferrocene-bound solid phase can separate and purify cucurbiturilderivative-bound BSA from the protein mixture.

The eluate was freeze-dried to obtain a cucurbituril derivative-boundBSA protein.

EXAMPLE 11 Purification of Antigen

In this example, an antigen that specifically binds to an antibody waspurified using the allyloxycucurbit[7]uril-conjugated solid phaseobtained in Example 7 and a ferrocene derivative-conjugated antibody.

(1) Preparation of Cucurbituril Derivative-Bound Solid Phase

300 mg of the allyloxycucurbit[7]uril-bound solid phase obtained inExample 7 in an excess of HEPES solution (50 mM, pH 8.5) was centrifugedat 10,000 rpm for 5 minutes. The supernatant was removed using a 200-μLpipette, and the remaining solid phase was washed twice.

(2) Preparation of Ferrocene Derivative-Bound Anti-BSA Protein Solution

A ferrocene derivative-bound anti-BSA protein solution was prepared asfollows.

15 mg of the N-(ferrocenyl methyl)-6-amino caproic acid (Fc-aca)obtained in (1) of Example 8, 6 mg of N-hydrosuccinimide (NHS, FlukaCorp.), and 9 mg of N-(3-dimethylaminopropyl)-N-ethylcarbodiimidehydrochloride (EDC, Fluka Corp.) were dissolved in 0.3 mL of ananhydrous DMF solution, and stirred for 30 minutes after the temperaturewas raised to 90° C. in a nitrogen atmosphere. The reaction was furtherperformed for 30 minutes while the temperature of the solution wasmaintained at 80° C. Then, the temperature of the solution was cooled toroom temperature. 30 μL of the reaction mixture was added into asolution of 7 mg of an anti-BSA solution (Sigma Co.) in 1 mL of aphosphate buffer solution (100 mM) at 2-minute intervals. The mixturewas shaken at room temperature for a day and centrifuged to separate aprecipitate. The filtrate was dialyzed in a 50-mM phosphate buffersolution (pH 7.4) for 30 hours to obtain an anti-BSA conjugated withN-(ferrocenyl methyl)-6-amino caproic acid (Fc-aca)(ferrocene-conjugated BSA).

A solution of an anti-body protein of the ferrocene-conjugated anti-BSAwas diluted with 50 mM of HEPES (pH 7.4) to a concentration of 100 μg/mLand a volume of 500 μL. (The antibody protein solution was subjected todialysis or gel filtration chromatography before use to remove externalproteins or other samples including azide, glycine, TRIS, and primaryamine groups)

(3) Binding of the Allyloxycucurbit[7]uril-Bound Solid Phase andFerrocene Derivative-Bound Anti-BSA Protein

The allyloxycucurbit[7]uril-bound solid phase prepared in (1) wassuspended in 500 μL of HEPES solution (50 mM, pH 7.4). 500 μL of thesolution of the antibody of the ferrocene-bound anti-BSA, which wasdiluted to 100 μg/mL in (2), was added into the suspension.

The mixed solution was slowly stirred at room temperature in a dark roomfor 3 hours. Next, particles were washed twice with a HEPES buffersolution (pH 7.4). Next, 500 μL of a blocking buffer solution (0.1 Methanol amine and HEPES buffer solution) was added. Next, the solidphase was washed twice with 500 μL of the HEPES buffer solution (pH7.4).

(4) Purification of Antigen

A complex of the ferrocene derivative-bound anti-BSA protein and theallyloxycucurbit[7]uril-bound solid phase was put into two tubes. 500 μLof a buffer solution containing lysozyme (1 mg/mL) was added into one ofthe two tubes as a control group, and 500 μL of a buffer solutioncontaining BSA (1 mg/mL) was added into the other tube.

The tubes each containing the solid phase and one of the proteinsolutions were slowly stirred at room temperature in a dark room for 3hours. Solid phase particles were washed twice with a HEPES buffersolution (pH 7.4).

A solid support treated with the buffer solution containing lysozyme asa control group and a solid support treated with the buffer solutioncontaining BSA were extracted using 300 μL of an elution buffer solution(0.1 M glycine).

After the protein was denaturized at a temperature of 60° C. or less,Coomassie blue was added into 150 μL of the elution solution, loadedonto an SDS-PAGE, and subjected to electrophoresis at 10 mA for 5 hours.At this time, molecular weight markers were also loaded onto theSDS-PAGE.

Next, the SDS-PAGE gel was separated from the electrophoretic apparatus,washed, dipped in Coomassie blue for 1 hour, and washed with a washingsolution overnight.

The degree of staining of the gel was measured using a gel scanner. Theresults are shown in FIG. 13. Lane 1 in FIG. 13 represents molecularweight markers, and Lanes 2 and 3 are the results of staining obtainedby loading the lysozyme-containing solution and the BSA-containingsolution, respectively.

Referring to FIG. 13, in the solid support treated with thelysozyme-containing solution (Lane 2), no protein was detected. In thesolid support treated with the BSA-containing solution (Lane 3), a bankof 66 kDa appeared, indicating that BSA can be separated using thecomplex of the cucurbituril-bound solid phase and the ferrocenederivative-bound anti-BSA.

EXAMPLE 12 Sensor Chip

(1) Immobilization of Allyloxycucurbit[7]uril onto Gold Surface

A flat gold electrode (2 cm×1 cm) was dipped in an ethanol solutioncontaining 1 mM of 1,8-octanedithiol for 2 hours to immobilize thiolgroups onto a surface of the gold substrate. The gold substrate wasdipped in a DMF solution in which the allyloxycucurbit[7]uril (1 mM)prepared in Example 3 had been dissolved, and irradiated with UV of 254nm and 300 nm for 1 hour. The gold substrate was drawn out of the DMFsolution and washed with DMF to obtain the gold electrode to which theallyloxycucurbit[7]uril was covalently bound (refer to FIG. 14).

(2) Inclusion of Ferrocene Molecules into Allyloxycucurbit[7]urilImmobilized on Gold Surface

In the present example, it was confirmed whether ferrocene moleculescould be included into cavities in the allyloxycucurbit[7]uril.

Initially, the gold electrode to which the allyloxycucurbit[7]uril wascovalently bound in (a) was dipped in a 0.2M ferrocene trimethylammoniumiodide solution (pH 6.2) for 1 hour. In addition, the inclusion offerrocene trimethylammonium iodide into the cavities ofallyloxycucurbit[7]uril was confirmed through a Fourier-transforminfrared absorption experiment (refer to FIGS. 15 and 16).

FTIR spectrum of ferrocene trimethyl ammonium iodide (refer to FIG. 15):1483, 1473, 1459, 1445, 1409, 1386, 1247 cm−1;

FTIR spectrum of the allyloxycucurbit[7]uril (refer to FIG. 16): 1756,1471, 1377, 1322, 1255 cm−1;

FTIR spectrum of the reaction product between the gold electrode towhich the allyloxycucurbit[7]uril was covalently bound and ferrocenetrimethylammonium iodide (refer to FIG. 17): 1755, 1483, 1473, 1459,1409, 1386, 1317, 1247 cm−1

(3) Inclusion of Ferrocene-Bound Glucose Oxidase intoAllyloxycucurbit[7]uril Immobilized on Gold Surface and EnzymeticActivity Measurement

An enzyme solution of ferrocene-bound glucose oxidase (Fc-GOx) wasprepared in the same manner as in (2) of Example 8, except that aglucose oxidase, instead of BSA, was used.

Next, a gold electrode to which the allyloxycucurbit[7]uril wasimmobilized on its surface in (1) was dipped in a 0.1 M phosphate buffersolution (200 Uml-1-glucose oxidase, pH 6.3) containing 10 mL of theenzyme solution of ferrocene-bound glucose oxidase (Fc-GOx) at roomtemperature for 30 minutes. The gold electrode was drawn out of thephosphate buffer solution and washed with 0.1M phosphate buffer solution(pH 6.3). The activity of the glucose oxidase included into theallyloxycucurbit[7]uril was measured after the gold electrode was dippedin 0.1M glucose solution (10 mL of 0.1 M phosphate buffer solution, pH6) at 25° C. for 1 minute to culture the enzyme. After the goldelectrode was removed from the glucose solution, 100 μl of a peroxidasesolution (50 purpurogallin units m1-1) and 20 μl of a o-dianisidine.2HClsolution (1% m/v in water) were added into the glucose solution, and themixed solution was poured into a glass cell. The enzymetic activity wasmeasured as the absorbance at 460 nm (refer to FIG. 18).

The absorbance of light at 460 nm signifies the activity of glucoseoxidase. In particular, hydrogen peroxide is generated as a result ofthe reaction between glucose and the glucose oxidase. As peroxidasereacts with the hydrogen peroxide and oxidizes o-dianisidine.2HCl, lightabsorption occurs at 460 nm. Accordingly, the activity of the enzyme canbe measured as the absorbance of light at 460 nm.

(4) Electrochemical Measurement

To measure the glucose concentration of a sample, the amount of H2O2,which is a product from the enzymetic reaction on glucose, was measured.The gold electrode manufactured in (1) was used to measure theconcentration of H2O2. The glucose oxidase was dissolved in a 0.1-Mphosphate buffer solution to a concentration of 10-120 mM. Everyexperiment was performed in a 25° C.-incubator.

A calibration curve was obtained based on the results of the experiments(refer to FIG. 19).

EXAMPLE 13 Solid Catalyst

(1) Preparation of N-(ferrocenyl methyl)-6-amino caproic acid(Fc-aca)-conjugated lipase

15 mg of the N-(ferrocenyl methyl)-6-amino caproic acid (Fc-aca)prepared in (1) of Example 8, 6 mg of N-hydrosuccinimide (NHS, FlukaCorp), and 9 mg of N-(3-dimethylaminopropyl)-N-ethylcarbodiimidehydrochloride (EDC, Fluka Corp.) were dissolved in 0.3 mL of ananhydrous DMF solution and stirred for 30 minutes after the temperaturewas raised to 90° C. in a nitrogen atmosphere. The reaction was furtherperformed for 30 minutes while the temperature of the solution wasmaintained at 80° C. 30 μL of the reaction mixture was added into asolution of 7 mg of lipase in 1 mL of a phosphate buffer solution (100mM) at 2-minute intervals. The mixture was shaken at room temperaturefor a day and centrifuged to separate a precipitate. The filtrate wasdialyzed in a 50-mM phosphate buffer solution (pH 7.4) for 30 hours toobtain an N-(ferrocenyl methyl)-6-amino caproic acid (Fc-aca)-boundlipase (ferrocene-bound lipase).

(2) Inclusion of Ferrocene-Bound Lipase Particles intoHydroxycucurbit[7]uril Immobilized on Solid Support

1.0 g of the hydroxycucurbit[7]uril immobilized on the polymer resin inExample 6 was put into a 10-mL disposable syringe, and 40 mL of CH2Cl2was continuously flowed at a rate of 1.3 mL/min. Next, the resin waswashed with 50 mL of DMF at a rate of 0.7 mL/min. 2 mg of theferrocene-bound lipase obtained in (1) was dissolved in a phosphatebuffer solution (0.1M, pH 7.4) and slowly flowed into a column at a rateof 0.7 mL/min. Next, the syringe was washed with 50 mL of water at arate of 2 mL/min. Next, polymer particles of the polymer support withthe hydroxycucurbit[7]uril immobilized thereon and into which theferrocene-bound lipase was included in the syringe was collected thesyringe and dried in a vacuum.

The resulting polymer resin including the ferrocene-bound lipaseparticles in the hydroxycucurbit[7]uril immobilized on the solid supportwas used as a catalyst.

(3) Epoxidation of α-Pinene

After 2.85 mL of α-pinene (15 mmol) and 2.37 mL of octanoic acid (15mmol) were dissolved in 8 mL of toluene, 150 mg of the catalyst obtainedin (2) was added into the solution. The mixture was slowly stirred atroom temperature to initiate reaction while gradually adding 2.6 mL ofH2O2 (23 mmol) into the mixture.

After 4 hours later, the reaction mixture was filtered to recovercatalyst particles. The filtrate was vaporized under reduced pressureand subjected to column chromatography to separate a product.

The separated α-pinene oxide compound was identified through 1H NMR, 13CNMR, and mass analysis. A portion of the organic phase was sampled at aregular time interval to identify the product.

α-pinene oxide: oil, boiling point: 102-104° C./50 mm:

¹H-NMR (CDCl₃, 300 MHz): δ=0.91 (3H, s, CH₃), 1.30 (3H, s, CH₃), 1.32(3H, s, CH₃), 1.59 (1H, m, CH), 1.72 (1H, m, CH), 1.90-2.05 (4H, m,CH₂), 3.08 (1H, m, CH);

¹³C-NMR (CDCl₃, 300 MHz): δ=60.23, 56.7, 44.9, 40.4, 39.6, 27.64, 26.72,25.87, 22.41, 20.18. MS (EI) m/z 152 (M⁺).

(4) Transesterification Between Methylacetoacetate and N-Butanol

2.1 mL of methylacetoacetate (20 mmol) and 1.8 mL of n-butanol (20 mmol)were added into 20 mL of toluene and stirred at 30° C. and 400 rpm for15 minutes. 155 mg of the catalyst (FerlipaseCB(7) polymer beads)prepared in (2) was added into the mixture to initiate reaction. A clearliquid sample was periodically sampled and analyzed using gaschromatography to identify n-butyl acetoacetate, which was the reactionproduct.

¹H-NMR (CDCl₃, 300 MHz): δ=2.12 (3H, s, CH₃), 3.46 (2H, s, CH₂), 4.05(2H, t, CH₂), 1.53 (2H, m, CH₂), 1.35 (2H, m, CH₂), 1.06 (3H, t, CH₃)

EXAMPLE 14 Measurement of Degree of Cell Death

After a ferrocene derivative bound to annexin V, which is known as aprotein that can selectively bind to surfaces of dead cells, was treatedon cells induced to die using an anti-cancer drug, the cells weretreated with an FITC-bound cucurbituril derivative, and the degree ofcell death was measured through flow cytometry.

(1) Induction of Cell Death by the Treatment with Anti-Cancer Drug

2 mL of RPMI-26040 culture solution (containing 10% FCS) and about 106KB cells (oral carcinoma cells) (obtained from the Korean Cell Line Bank(KCLB)) were cultured in two 6-well cell culture dishes at 37° C. in a5% CO2 condition for 48 hours.

Next, 2 mL of the RPMT-1640 culture solution (containing: 10% FGS) inone of the 6-well cell culture dishes was replaced by the same, freshculture solution, and 2 mL of the RPMT-1640 culture solution in theother 6-well cell culture dish was replaced by 0.5 μM (0.3 μg/mL) ofdoxorubicin, and the two culture dishes were incubated at 37° C. in a 5%CO2 condition for 3 days.

(2) Treatment of Cells with Annexin V-Ferrocene Derivative

15 mg of the N-(ferrocenyl methyl)-6-amino caproic acid (Fc-aca)obtained in (1) of Example 8, 6 mg of N-hydrosuccinimide (NHS, FlukaCorp.), and 9 mg of N-(3-dimethylaminopropyl)-N-ethylcarbodiimidehydrochloride (EDC, Fluka Corp.) were dissolved in 0.3 mL of ananhydrous DMF solution, and stirred for 30 minutes after the temperaturewas raised to 90° C. in a nitrogen atmosphere.

The reaction was further performed for 30 minutes while the temperatureof the solution was maintained at 80° C. Then, the temperature of thesolution was cooled to room temperature. 30 μL of the reaction mixturewas added into a solution of 9 mg of annexin V (Sigma Corp.) in 1 mL ofa phosphate buffer solution (100 mM) at 2-minute intervals. The mixturewas shaken at room temperature for a day and centrifuged to separate aprecipitate. The filtrate was dialyzed in a 50-mM phosphate buffersolution (pH 7.4) for 30 hours to obtain an N-(ferrocenylmethyl)-6-amino caproic acid (Fc-aca)-bound annexin V (annexinV-ferrocene derivative).

The culture solution in the two cell culture dishes incubated in (1) wasremoved. The cell cultures in the dishes were washed twice with 2 mL ofa PBS buffer solution (pH 7.4, Sigma Corp.), and then 2 mL of aRPMT-1640 culture solution (including 10% FCS) containing 100 μL of anferrocene-annexin V reagent (including 10 μL of a 10× binding buffersolution (Trevigen Corp.), 1 μL of ferrocene-annexin V, and 89 μL ofdistilled water) was added into the culture dishes and incubated at 37°C. in a 5% CO2 condition for 2 hours.

Next, the culture solution was removed from the two cell culture dishes,and each of the cell cultures was washed twice with 2 mL of a PBS buffer(pH 7.4, Sigma Corp.) and dipped in 2 mL of a PBS buffer solution (pH7.4, Sigma Corp.) containing 2% formaldehyde for 15 minutes to fix thecells.

(3) Preparation of [3-(2-aminoethyl sulfanyl)propyl-O]14cucurbit[7]uril

3 mL of DMF, 50 mg (0.025 mmol) of the allyloxycucurbit[7]uril obtainedin Example 3, 87 mg (0.77 mmol) of 2-aminoethanothiol hydrochloride, and0.32 mg of AIBN were put into a quartz tube and sealed. The quartz tubewas charged with nitrogen using a freeze-pump-thaw degassing method andplaced in a reactor under 254 nm-UV radiation for 36 hours. Aftertermination of the reaction, the solvent was removed under reducedpressure, 0.5 mL of triethylamine was added into the quartz tube, andthe mixture was washed four times with 15 mL of diethylether. Theresulting compound was dried under reduced pressure to obtain 48 mg of afinal compound with a yield of 62%.

1H NMR (300 MHz, DMSO): δ=5.56 (d, J=14.3 Hz, 14H), 4.05 (d, J=14.3 Hz,14H), 3.52 (m, 28H), 2.91 (m, 28H), 2.62 (m, 56H), 1.84 (t, 28H); ¹³CNMR (75 MHz, DMSO): δ=151.8, 95.5, 63.2, 40.8, 38.1, 33.4, 32.2 26.2; MS(MALDI-TOF): m/z 3048.1 [M+Na+].

(4) Treatment of FITC-Cucurbituril Derivative

100 mg (0.033 mmol) of [3-(aminoethyl sulfanyl)propyl-O]14cucurbit[7]uril and 1 mL of 1M NaOH were added into 5 mL of DMSO, and asolution of 28.26 mg (0.072 mmol) of FITC dissolved in 8 mL of DMSO wasadded into the solution and stirred at room temperature for 12 hours.

10 mL of distilled water was added dropwise into the reaction containerto neutralize the reaction solution. The neutralized solution wasdialyzed for 12 hours, and the solvent was removed through distillationunder reduced pressure to obtain 75 mg of a final product in white solidform with a yield of 60%.

The final product was stored in a 4° C., light-shielded refrigerator.

¹H NMR (300 MHz, DMSO): =10.5 (s, 2H), 9.9 (br, 2H), 8.2 (s, 2H), 7.9(m, 2H), 7.3 (m, 2H), 6.4 6.7 (m, 12H), 5.56 (d, J=14.3 Hz, 14H), 4.05(d, J=14.3 Hz, 14H), 3.52 (m, 28H), 2.91 (m, 28H), 2.62 (m, 56H), 1.84(t, 28H).

The buffer solution was removed from the two cell culture dishes, andeach of the cell cultures was washed twice with 9 mL of a PBS buffersolution (Simga Corp.) and dipped for 15 minutes in 9 mL of a PBS buffersolution (Sigma Corp.) in which 45 μg of the FITC-cucurbiturilderivative obtained above had been dissolved.

(5) Measurement of Degree of Cell Death

The cell samples in the PBS buffer solution were transferred intocentrifuge tubes, centrifuged to separate cells, and suspended in 500 μLof a PBS buffer solution.

Next, the degree of cell depth in each of the samples was measuredthrough flow cytometry (FACSCalibur, Becton Dickinson Corp., Ex=488 nm,Em=530 nm (for FITC detection).

As a result of the flow cytometry, a greater intensity FITC signal wasdetected from the sample treated with doxorubicin than the sample nottreated with doxorubicin, indicating that most cells in thedoxorubicin-treated sample died. In FIG. 20, (a) indicates KB cells nottreated with doxorubicin, and (b) indicates KB cells treated withdoxorubicin.

EXAMPLE 15 Separation of cucurbit[7]uril using affinity chromatography

(1) Adamantylamination of chloromethylated polystyrene

2.0 g of the chloromethylated polystyrene (cross-linked with 1%divinylbenzene) (chloromethylated Combigel XE-305) obtained in (1) ofExample 6 was sufficiently dipped in 17 mL of DMF for 2 hours. 1.59 g(8.5 mmol) of 1-adamantaneamine hydrochloride (TCI) was slowly addedinto 12.0 mL of a DMF-pyridine (1:2 v/v), and the chloromethylatedCombigel XE-305 in DMF was added into the solution and stirred at 55° C.for 43 hours. The reaction mixture was filtered with DMF, CH2Cl2,methanol, and then diethylether and washed. The washed reaction mixturewas dried in a vacuum to obtain an adamantylaminated CombiGel XE-305.

Element analysis: C, 61.73: H, 6.87, N, 5.43%

(These results confirm that 3.88 mmol of damantylamine was included in 1g of the adamantylaminated CombiGel XE-305.)

IR spectrum (refer to FIG. 21): 3022, 2935, 1630, 1483, 1213, 1153 cm⁻¹

(2) Separation of Cucurbit[7]uril Using Affinity Chromatography

1.0 g of the adamantylaminated CombiGel XE-305 (chloromethylated)obtained in (1) above was put into a 10-mL disposable syringe, and about20 mL of CH2Cl2 was flowed as a solvent. When CH2Cl2/TFA(trifluoroacetic acid) (45 mL/5 mL) was flowed at a rate of 1.3 mL tohydrogenate adamantylamine. Next, 50 mL of CH2Cl2 was flowed at a rateof 2 mL/min to wash the resin, and 50 mL of DMF was flowed at a rate of0.7 mL/min to swell the resin. 1 g of an unpurified cucurbit[7]urilmixture was dissolved in 30 mL of water and slowly flowed over the resinat a rate of 0.7 mL/min. Next, 50 ml of water was flowed at a rate of 2mL/min and then 50 mL of methanol was flowed at a rate of 0.7 mL/min towash the resin. DMF/TEA (triethylamine) (40 mL/20 mL) or an ammoniumbicarbonate solution was flowed at a rate of 2 mL/min to separate thecucurbit[7]uril from the resin. Next, 60 mL of water was flowed at arate of 2 mL/min to separate the cucurbit[7]uril from the resin. The twosolutions(DMF/TEA (triethylamine) (40 mL/20 mL) or an ammoniumbicarbonate solution and water solution) were concentrated to obtain awhite solid material, and the white solid material was washed withmethanol to obtain 240 mg of a final white solid material.

It was confirmed from 1H NMR data that the obtained white solid materialwas pure cucurbit[7]uril (having formula (2) where each of A1 and A2 isH, X═O, and n=7) not containing any homologues.

Cucurbit[7]uril: ¹H NMR (300 MHz, D₂O): δ=5.79 (d, J=15.4 Hz, 14H), 5.57(s, 14H), 4.28 (d, J=15.4 Hz, 14H).

In addition, the cucurbit[7]uril mixture was purified in the same manneras above except that the ferrocene-methylaminated Combigel XE-305obtained in (1) of Example 10, instead of the adamantylaminated CombiGelXE-305, was used. The same results as above are obtained.

(3) Separation of Hydroxycucurbit[7]uril Using Affinity Chromatography

The hydroxycucurbit[7]uril synthesized in Example 2 contained a largeamount of potassium salt. To obtain pure hydroxycucurbit[7]uril (havingformula (1) where both A1 and A2 are OH, X═O, and n=7), thehydroxycucurbit[7]uril mixture was dissolved in water and passed throughthe anamantylaminated CombiGel XE-305 resin. Pure hydroxycucurbit[7]urilwas separated in the same manner as in (2).

Hydroxycucurbit[7]uril: ¹H NMR (300 MHz, D₂O): δ=7.83 (s, 14H), 5.33 (d,14H), 4.42 (d, 14H)

In addition, the hydroxycucurbit[7]uril mixture was purified in the samemanner as above except that the ferrocene-methylaminated Combigel XE-305obtained in (1) of Example 10, instead of the adamantylaminated CombiGelXE-305, was used. The same results as above are obtained.

(4) Purification of Cucurbit[N]urils Having Different Substituents UsingAffinity Chromatography

A perhydroxycucurbit[7]uril mixture, a di-meta-aminophenylcucurbit[7]uril mixture, a dimethyl cucurbit[7]uril mixture, acucurbit[8]uril mixture, a hydroxycucurbit[8]uril mixture, acyclohexanocucurbit[7]uril mixture, a di-p-methoxyphenyl cucurbit[7]urilmixture, and a di-p-hydroxyphenyl cucurbit[7]uril mixture were purifiedusing the affinity chromatography used to purify the cucurbituril[7] in(2) above. As a result, it was confirmed that all the cucurbiturileswere purified.

While the present invention has been particularly shown and describedwith reference to exemplary embodiments thereof, it will be understoodby those of ordinary skill in the art that various changes in form anddetails may be made therein without departing from the spirit and scopeof the present invention as defined by the following claims.

1. A kit comprising: a first component that is a compound of formula (1)below bound to a first material; and a second component that is a ligandbound to a second material, wherein each of the first and secondmaterials is independently selected from the group consisting of a solidphase, a biomolecule, an antioxidant, a chemical therapeutic agent, ananti-histaminic agent, a cucurbituril dendrimer, a cyclodextrinderivative, a crown ether derivative, a calixarene derivative, acyclophane derivative, a cyclic peptide derivative, a metallic ion, achromophore, a fluorescent material, a phosphor, a radioactive material,and a catalyst; and the ligand can non-covalently bind to the compoundof formula (1) below, has at least one amine group, and is selected fromthe group consisting of a C₁-C₂₀ alkyl group; a C₂-C₂₀ alkenyl group; aC₂-C₂₀ alkynyl group; a C₁-C₂₀ alkoxy group; a C₁-C₂₀ aminoalkyl group;a C₄-C₂₀ cycloalkyl group; a C₄-C₇ heteroarylcyclo group; a C₆-C₂₀ arylgroup; a C₅-C₂₀ heteroaryl group; a C₁-C₂₀ alkylsilyl group; a C₆-C₂₀aryl group; a C₅-C₂₀ heteroaryl group; adamantane having a substitutedor non-substituted C₁-C₂₀ alkyl group, C₆-C₂₀ aryl group or C₅-C₂₀heteroaryl group; ferrocene or metallocene having a substituted ornon-substituted C₁-C₂₀ alkyl group, C₆-C₂₀ aryl group or C₅-C₂₀heteroaryl group; carborane having a substituted or non-substitutedC₁-C₂₀ alkyl group, C₆-C₂₀ aryl group or C₅-C₂₀ heteroaryl group;fullerene having a substituted or non-substituted C₁-C₂₀ alkyl group,C₆-C₂₀ aryl group or C₅-C₂₀ heteroaryl group; cyclam or crown etherhaving a substituted or non-substituted C₁-C₂₀ alkyl group, C₆-C₂₀ arylgroup or C₅-C₂₀ heteroaryl group; an oxygen-protected amino acid havinga substituted or non-substituted C₁-C₂₀ alkyl group, C₆-C₂₀ aryl groupor C₅-C₂₀ heteroaryl group; peptide having a substituted ornon-substituted C₁-C₂₀ alkyl group, C₆-C₂₀ aryl group or C₅-C₂₀heteroaryl group; alkaloid having a substituted or non-substitutedC₁-C₂₀ alkyl group, C₆-C₂₀ aryl group or C₅-C₂₀ heteroaryl group;cisplatin having a substituted or non-substituted C₁-C₂₀ alkyl group,C₆-C₂₀ aryl group or C₅-C₂₀ heteroaryl group; oligonucleotide having asubstituted or non-substituted C₁-C₂₀ alkyl group, C₆-C₂₀ aryl group orC₅-C₂₀ heteroaryl group; rhodamine having a substituted ornon-substituted C₁-C₂₀ alkyl group, C₆-C₂₀ aryl group or C₅-C₂₀heteroaryl group; and a nanoparticle having a substituted ornon-substituted C₁-C₂₀ alkyl group, C₆-C₂₀ aryl group or C₅-C₂₀heteroaryl group,

where n is an integer from 6 to 10; X is O, S or NH; each of A₁ and A₂is independently H, OR, SR, or NHR, and A₁ and A₂ are not simultaneouslyH, where R is selected from the group consisting of H; a substituted ornon-substituted C₁-C₃₀ alkyl group; a substituted or non-substitutedC₂-C₃₀ alkenyl group; a substituted or non-substituted C₂-C₃₀ alkynylgroup; a substituted or non-substituted C₂-C₃₀ carbonylalkyl group; asubstituted or non-substituted C₁-C₃₀ thioalkyl group; a substituted ornon-substituted C₁-C₃₀ alkylthiol group; a substituted ornon-substituted C₁-C₃₀ hydroxyalkyl group; a substituted ornon-substituted C₁-C₃₀ alkylsilyl group; a substituted ornon-substituted C₁-C₃₀ aminoalkyl group; a substituted ornon-substituted C₁-C₃₀ aminoalkylthioalkyl group; a substituted ornon-substituted C₅-C₃₀ cycloalkyl group; a substituted ornon-substituted C₂-C₃₀ heterocycloalkyl group; a substituted ornon-substituted C₆-C₃₀ aryl group; a substituted or non-substitutedC₆-C₃₀ arylalkyl group; a substituted or non-substituted C₄-C₃₀heteroaryl group; and a substituted or non-substituted C₄-C₃₀heteroarylalkyl group.
 2. The kit of claim 1, wherein one of the firstand second materials is a biomolecule, and the other is a chromophore, afluorescent material, or a phosphor.
 3. The kit of claim 1, wherein thesolid phase is a solid support selected from the group consisting of apolymer, a resin, a magnetic material, a silicagel, a polymer- orgold-coated silicagel, a zirconium oxide, a monolithic polymer, apolymer-coated magnetic particle, a gold thin film, a silver thin film,glass, an ITO-coated glass, silicon, a metal electrode, a nanorod, ananotube, a nanowire, curdlan gum, cellulose, a nylon film, sepharose,and sephadex.
 4. The kit of claim 3, wherein the solid phase ispolystyrene resin or polymer-coated silicagel.
 5. The kit of claim 1,wherein the biomolecule is selected from the group consisting of anenzyme, a nucleic acid, a protein, an amino acid, an antibody, anantigen, an inhibitor, a vitamin, a cofactor, a fatty acid, a cell, acell membrane, a substrate, a substrate analogue, a suppressor, acoenzyme, a virus, lectin, a polysaccharide, a glucoprotein, a receptor,histone, ATP, ADP, a hormone, a receptor, and glutathione.
 6. The kit ofclaim 5, wherein the enzyme is selected from the group consisting ofcellulase, hemicellulase, peroxidase, protease, amylase, xylanase,lipase, esterase, cutinase, pectinase, keratinase, reductase, oxidase,phenoloxidase, lipoxigenase, ligninase, pullulanase, arabinosidase,hyaluronidase, and a combination thereof.
 7. The kit of claim 1, whereinthe catalyst is a Grobbs catalyst, a radical initiator, or a combinationthereof.
 8. The kit of claim 1, wherein, in said formula (1), each of A₁and A₂ is independently H, OR, SR, or NHR where R is a substituted ornon-substituted C₂-C₃₀ alkenyl group.
 9. The kit of claim 1, wherein, insaid formula (1), n is 7, and X is O.
 10. The kit of claim 1, whereinthe ligand is adamantane, ferrocene, or metallocene that have at leastone amine group and a substituted or non-substituted C₁-C₂₀ alkyl group,C₆-C₂₀ aryl group or C₅-C₂₀ heteroaryl group.
 11. The kit of claim 10,wherein the amine group is a primary amine, a secondary amine, or ahydrogenated amine.
 12. The kit of claim 10, wherein the ligand isadamantanamine or ferrocene methylamine.